Global Addison's Disease Drugs Market – Industry Trends and Forecast to 2031

Análisis y tamaño del mercado de medicamentos para la enfermedad de Addison

La terapia de reemplazo hormonal (TRH) es una aplicación fundamental dentro del mercado de medicamentos para la enfermedad de Addison. Implica la administración de hormonas sintéticas o bioidénticas para reemplazar los niveles deficientes de cortisol y aldosterona en individuos con insuficiencia suprarrenal. La TRH tiene como objetivo restablecer el equilibrio hormonal, aliviar síntomas como la fatiga, la debilidad muscular y la presión arterial baja, y prevenir complicaciones como las crisis suprarrenales. Estos medicamentos se toman típicamente por vía oral, aunque también se pueden utilizar vías de administración alternativas, como parches transdérmicos o inyecciones. Una terapia de reemplazo hormonal eficaz es crucial para controlar la enfermedad de Addison, mejorar la calidad de vida de los pacientes y reducir el riesgo de crisis suprarrenales potencialmente mortales.

El tamaño del mercado mundial de medicamentos para la enfermedad de Addison se valoró en USD 610,51 millones en 2023 y se proyecta que alcance los USD 1.357,04 millones para 2031, con una CAGR del 10,50% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado       

Definición de mercado

La enfermedad de Addison, también conocida como insuficiencia suprarrenal primaria, es un trastorno endocrino poco frecuente que se caracteriza por la producción inadecuada de hormonas por parte de las glándulas suprarrenales. Esta deficiencia afecta principalmente al cortisol y la aldosterona, hormonas cruciales para regular el metabolismo, la función inmunitaria y la presión arterial. Los síntomas incluyen fatiga, pérdida de peso, debilidad muscular, presión arterial baja y oscurecimiento de la piel. La enfermedad de Addison puede ser consecuencia de trastornos autoinmunes, infecciones o daño de la glándula suprarrenal, y requiere terapia de reemplazo hormonal de por vida para su control.

Dinámica del mercado de medicamentos para la enfermedad de Addison

Conductores

• La creciente prevalencia de la enfermedad de Addison promueve la demanda de medicamentos

Esta creciente población de pacientes impulsa la demanda de medicamentos para controlar los síntomas, lo que lleva a las empresas farmacéuticas a invertir en investigación y desarrollo. Según un artículo titulado "Insuficiencia suprarrenal en pacientes", publicado en junio de 2021, factores como la hiperplasia suprarrenal congénita y la creciente incidencia de la tuberculosis contribuyen aún más a esta tendencia. Con aproximadamente 7.860 casos de tuberculosis notificados en EE. UU. en 2021, existe una población significativa en riesgo de sufrir insuficiencia suprarrenal. En consecuencia, el mercado de medicamentos para la enfermedad de Addison se está expandiendo para satisfacer la creciente demanda, fomentando el crecimiento y la innovación en el sector farmacéutico.

• Los crecientes avances tecnológicos proporcionan sistemas mejorados de administración de medicamentos

Las innovaciones, como los mecanismos de administración de fármacos dirigidos y los dispositivos portátiles para el seguimiento continuo, permiten un tratamiento más preciso y cómodo de la enfermedad. Las pruebas genéticas avanzadas y la identificación de biomarcadores ayudan a la detección temprana y a los enfoques de tratamiento personalizados. Además, los avances en la investigación farmacéutica, incluido el uso de nuevas formulaciones de fármacos y análogos de hormonas sintéticas, contribuyen a mejorar la eficacia y el cumplimiento del tratamiento por parte de los pacientes. Estas innovaciones tecnológicas contribuyen a mejorar los resultados de los pacientes, lo que impulsa la demanda de medicamentos para la enfermedad de Addison en el mercado.

Por ejemplo,

En enero de 2022, el anuncio de Antares Pharma de los prometedores resultados de la fase I de ATRS-1902 significa un avance significativo en la medicación de la enfermedad de Addison. ATRS-1902 introduce una innovadora administración dirigida de fármacos para la insuficiencia suprarrenal aguda, lo que refleja la creciente preferencia por enfoques de tratamiento precisos y convenientes. Este avance sugiere posibles mejoras en el bienestar del paciente y una mayor demanda de terapias especializadas en el mercado.

Oportunidades

• Expansión de los medicamentos para la enfermedad de Addison debido a la creciente población geriátrica

As individuals age, the risk of developing Addison's disease increases, leading to a higher prevalence of this condition among older adults. This demographic trend results in greater demand for drugs to manage the symptoms and complications associated with Addison's disease among the elderly population. Consequently, pharmaceutical companies may focus on developing and marketing drugs tailored to the specific needs of older patients, driving market growth. Healthcare providers may prioritize screening and treatment for Addison's disease in geriatric patients, further fueling demand for related drugs.

• Rising Healthcare Expenditure Advantages Pharmaceutical Companies for the Development of Innovative Drugs

As healthcare budgets expand, patients with Addison's disease may have better access to specialized care and medications, driving demand for drugs targeting this condition. Higher healthcare spending often correlates with improved infrastructure and services, facilitating earlier diagnosis and treatment initiation for Addison's disease patients. This trend fosters a conducive environment for pharmaceutical companies to invest in research and development of innovative drugs, thereby fueling growth in the Addison's disease drugs market.

Restraints/Challenges

• High Treatment Costs Limits Patient from the Adoption of Medications

The financial burden associated with ongoing treatment can deter individuals from seeking or adhering to prescribed medications, leading to suboptimal management of the condition. Additionally, for some patients, the expense may outweigh the perceived benefits of the drugs, further limiting their willingness to engage in treatment. This barrier underscores the need for affordable options and innovative pricing strategies to improve access to medications and alleviate the financial strain on patients grappling with Addison's disease.

• Regulatory Hurdles Limits the Adoption of Addison's Disease Drugs

Developing drugs for rare conditions such as Addison's disease encounters challenges in navigating complex regulatory pathways. While regulatory agencies offer expedited approval processes for orphan drugs, meeting stringent criteria and documentation requirements can prolong development timelines and increase costs. Additionally, ensuring compliance with evolving regulations adds further complexity, potentially discouraging investment in research and development for Addison's disease treatments. These regulatory barriers limit the availability of innovative therapies, hindering market growth and patient access to effective treatments.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In April 2022, Diurnal Group expanded its distribution agreement with Er-Kim to cover Greece, Cyprus, and Malta, encompassing the marketing and distribution of Alkindi and Efmody, two medications used for Addison's disease treatment. This extension aims to enhance accessibility to these drugs in the specified regions
• In January 2022, Antares Pharma received Fast Track designation from the FDA for ATRS-1902, designed for adrenal crisis rescue in adults and adolescents. Leveraging their Vai auto-injector platform, this designation acknowledges the potential of ATRS-1902 to address critical needs in adrenal crisis management, offering a stable liquid hydrocortisone formulation
• In November 2020, Spruce Biosciences reported positive outcomes from their Phase 2 trial evaluating tildacerfont for congenital adrenal hyperplasia (CAH), often linked with Addison's disease. These results signify progress in developing innovative therapies for conditions associated with adrenal insufficiency, potentially broadening treatment options for affected individuals
• In April 2020, The FDA granted approval for Recorlev (levoketoconazole) as a therapy for endogenous Cushing's syndrome, a disorder sometimes related to Addison's disease. This approval marks a significant milestone in addressing conditions associated with adrenal dysfunction, potentially offering relief to patients with overlapping symptoms of Addison's disease and Cushing's syndrome

Addison's Disease Drugs Market Scope

The market is segmented on the drug class, route of administration, distribution channel and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Glucocorticoid
• Mineralocorticoid
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Addison's Disease Drugs Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the market primarily due to its robust healthcare infrastructure, extensive presence of key industry players, increasing demand for Addison’s disease treatment options, and a growing focus on research and development activities within the region. These factors collectively contribute to North America's dominance in supplying effective medications for managing Addison’s disease, positioning it as a key hub for advancements and innovation in this field.

The Asia-Pacific is expected to experience growth in the market due to heightened government efforts to raise awareness, a surge in medical tourism, increasing research endeavors, and the presence of vast undiscovered markets. With a large population base and escalating demand for quality healthcare, the region offers significant opportunities for the advancement and uptake of Addison's disease treatments.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Addison's Disease Drugs Market Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related market.

Some of the major players operating in the market is:

• Bristol-Myers Squibb Company (U.S.)
• Merck & Co., Inc (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc (U.S.)
• Bio-Techne (U.S.)
• GSK plc. (U.S.)
• Lupin (India)
• Abbott (U.S.)
• Amgen Inc (U.S.)
• Bayer AG (Germany)
• Lilly (U.S.)

SKU-53539